Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer

The goal of this study is to evaluate the efficacy and safety of oral paclitaxel solution plus fruquintinib as second-line therapy in adult subjects with advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.

Trial Details

NCT ID
NCT07552402
Phase
NA
Sponsor
Harbin Medical University
Status
RECRUITING
Cancer Type
Gastroesophageal Junction (GEJ) Gastric Cancer
Interventions
  • Oral Paclitaxel Solution Plus Fruquintinib
  • Investigator Choice (IC) Chemotherapy
Locations (sample)
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Nanning, Guangxi, China|22.81667,108.31667
  • Shijiazhuang, Hebei, China|38.04139,114.47861
  • Harbin, Heilongjiang, China|45.75,126.65
  • Qiqihar, Heilongjiang, China|47.33922,123.96154

Key Eligibility Criteria

  • Age 18 to 75 years, regardless of sex;
  • Histologically and/or cytologically confirmed advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma that has failed first-line therapy…
  • Presence of at least one measurable lesion per RECIST v1.1 criteria (Note: Previously irradiated lesions cannot be used as target lesions unless un…
  • Body weight ≥40 kg or BMI \>18.5 kg/m²;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastroesophageal Junction (GEJ) Gastric Cancer Trials on Trialify →